Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.35 |
| ▸ | F2 | P00734 | 6/20 | 0.34 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765440 | 0.86 | F7 (0.39) | MAPK1F2PRSS1 | |
| SCHEMBL30765645 | 0.86 | MAPK1 (0.35) | MAPK1NAMPTF2 | |
| SCHEMBL30765462 | 0.85 | MAPK1 (0.35) | MAPK1SOS1F2PRSS1 | |
| SCHEMBL30765686 | 0.84 | F2 (0.35) | MAPK1NAMPTF2 | |
| SCHEMBL30765753 | 0.84 | F2 (0.34) | MAPK1F2PRSS1 | |
| SCHEMBL30765646 | 0.83 | MAPK1 (0.38) | MAPK1NAMPTF2 | |
| SCHEMBL30765748 | 0.82 | SOS1 (0.40) | MAPK1SOS1LIPGEGFR | |
| SCHEMBL30765806 | 0.82 | MAPK1 (0.36) | MAPK1NAMPTF2 | |
| SCHEMBL30765642 | 0.82 | MAPK1 (0.35) | MAPK1NAMPTF2 | |
| SCHEMBL30765603 | 0.81 | F2 (0.35) | MAPK1NAMPTF2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |